ArticleInternational cancer conference journal2023
Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: a case report and literature review.
Article in International cancer conference journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 7 citations in OpenAlex.
- Brugada Phenocopy Associated With the Tyrosine Kinase Inhibitor Avapritinib During Febrile Illness.JACC. Case reports · 2026Article
- Entrectinib results in ventricular tachycardia and Brugada phenocopy through inhibition of sodium current.Cardio-oncology (London, England) · 2026Article
- Article
- Refractory ventricular tachyarrhythmias following entrectinib initiation in metastatic lung adenocarcinoma: a case report.Journal of medical case reports · 2025Article
- Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent Toxicity.JACC. CardioOncology · 2025Review
- Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer.International journal of molecular sciences · 2025Review
- Entrectinib-Induced Brugada Syndrome Leading to Ventricular Tachycardia in A Patient with ROS1 Fusion-Positive Lung Adenocarcinoma.European journal of case reports in internal medicine · 2025Article
- ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Entrectinib, a multikinase inhibitor of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.